ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lisocabtagene maraleucel

Also written as “Liso-cel”, “JCAR017” and “JCAR017 (lisocabtagene maraleucel)”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.

Drug pageLisocabtagene maraleucel: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 19, 202310 company-led studies, 3 open or runningNext primary completion: Nov 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb103 open or runningphase 3since Dec 19, 2023Dec 11, 2015Nov 26, 2027phase 2 · NCT03331198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2015First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT02631044 · 387 enrolled · United States
  2. Oct 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198 · 320 enrolled · United States, Canada
  3. Mar 23, 20182 phase 2 studies in Lymphoma, Non-HodgkinNCT03483103, NCT03484702
  4. Jun 9, 2018Named lisocabtagene maraleucelINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JCAR017
  5. Oct 18, 2018Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03743246 · 21 enrolled · United States, France, Germany and more
  6. Nov 7, 2018Phase 2 study in Lymphoma, Non-HodgkinNCT03744676 · 104 enrolled · United States
  7. Jan 27, 2020Phase 2 study in Lymphoma, Non-HodgkinNCT04245839 · 276 enrolled · United States, Austria, Canada and more
  8. Dec 19, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06205290 · United States, Austria, Belgium and more
  9. Feb 26, 2024Phase 3 study in RecurrenceNCT06313996
  10. Jun 3, 2025Phase 2 study in LymphomaNCT07015242 · 65 planned · United States, France, Germany

Ahead

  1. Nov 26, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198
  2. Jan 9, 2028Primary completion: phase 2 study in LymphomaNCT07015242
  3. Sep 30, 2031Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT04245839

TargetBeta

CD19 →read by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07015242Lymphoma · United States, France, Germany2RecruitingJan 9, 202865
NCT06313996Recurrence3WithdrawnOct 16, 20310
NCT06205290Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more3WithdrawnOct 13, 20310
NCT04245839Lymphoma, Non-Hodgkin · United States, Austria, Canada and more2Active, not recruitingSep 30, 2031276
NCT03744676Lymphoma, Non-Hodgkin · United States2CompletedSep 22, 2023104
NCT03743246Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more2TerminatedJan 26, 202421
NCT03484702Lymphoma, Non-Hodgkin · Austria, Belgium, Finland and more2CompletedDec 15, 2023113
NCT03483103Lymphoma, Non-Hodgkin · United States2CompletedSep 24, 202174
NCT03331198Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada2Active, not recruitingNov 26, 2027320
NCT02631044Lymphoma, Non-Hodgkin · United States1CompletedMay 16, 2024387

How it is read

Names in the registry

  • “Liso-cel”, 3 entries
  • “JCAR017”, 3 entries
  • “lisocabtagene maraleucel”, 2 entries
  • “JCAR017 (lisocabtagene maraleucel)”, 1 entry
  • “JCAR017 (lisocabtagene maraleucel) + ibrutinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.